Therapeutic Authority and the Red Eye That Must Be Referred
An optometrist with New Jersey therapeutic pharmaceutical agent authority sees two patients on a busy Saturday. Patient A is a 24-year-old contact lens wearer with a 2-mm corneal infiltrate, pain, photophobia, and mild anterior chamber reaction; visual acuity is 20/60. Patient B has a branching dendritic corneal ulcer, reduced corneal sensation, and a history of cold sores. The optometrist has topical fluoroquinolone, topical steroid, cycloplegic, and oral antiviral medications in the office. He considers treating both patients himself because he has prescriptive authority and the office is far from an ophthalmologist. Patient A improves slightly after one hour of topical antibiotic; Patient B asks for a steroid drop to 'calm the redness.' The optometrist must decide what to prescribe, what to refer, and how to document the risk discussion.
1. For Patient A, what is the scope of optometric treatment, and when must the optometrist refer?
Read the worked answer
A corneal infiltrate in a contact lens wearer is potentially a sight-threatening microbial keratitis. The optometrist may begin topical fluoroquinolone and cycloplegia within therapeutic authority, but must culture or refer according to severity and must arrange close follow-up, often within 24 hours. Referral is required if the infiltrate is large, central, associated with significant anterior chamber reaction, hypopyon, worsening pain, or if the patient cannot adhere to frequent drops. Because Patient A has a 2-mm infiltrate and 20/60 vision, same-day ophthalmology consultation is prudent, especially if there is any doubt about compliance. The optometrist should not patch the eye or use a steroid initially. Scope authority is not a mandate to treat everything; the standard of care and public protection require recognizing limits.
2. For Patient B, may the optometrist prescribe a topical steroid? Explain.
Read the worked answer
No. A dendritic ulcer is characteristic of herpes simplex epithelial keratitis. Topical corticosteroids are contraindicated in active epithelial herpes simplex virus because they can promote viral replication and cause severe stromal disease or perforation. The optometrist should not accede to the patient's request. Treatment is topical antiviral therapy, with ophthalmology co-management for any stromal involvement, large defect, or uncertainty. If the optometrist has antiviral agents and experience, he may start treatment and refer; but a steroid is the wrong choice regardless of prescriptive authority. The case tests the difference between having a drug in the office and having legal and clinical authority to use it appropriately. Document the refusal of steroids, the rationale, and the referral.
3. What documentation and communication steps reduce risk in both cases?
Read the worked answer
For each patient: record visual acuity, slit-lamp findings including infiltrate size and location, dendrite, anterior chamber reaction, intraocular pressure if indicated, and risk factors such as contact lens wear and cold sores. Document the diagnosis, medications with dose and frequency, follow-up interval, and specific return precautions. For referrals, record the ophthalmologist contacted, appointment time, and that the patient understood. For Patient B, document that steroid was requested and declined because of herpes simplex virus risk. For Patient A, document that same-day referral was offered and why. Communication should include written instructions and a phone number. Good records show the optometrist stayed within scope and put patient safety first, which is the core of the Board's mandate.